COMMUNIQUÉS West-GlobeNewswire

PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes
10/03/2026
The European Medicines Agency (EMA) has officially qualified PolTREG to submit an application for marketing authorization in the European Union for the PolTREG-T1D cell preparation. GDAŃSK, Poland, March 10, 2026 (GLOBE [...]
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
10/03/2026
A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic MELBOURNE, Australia, March 10, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company [...]
Imprivata Introduces Agentic Identity Management to Secure and Govern AI Agents in Healthcare
10/03/2026
New capabilities enable healthcare organizations to deploy AI agents that improve clinician productivity while maintaining secure, compliant access across modern and legacy systems WALTHAM, Mass., March 10, 2026 (GLOBE [...]
Smith+Nephew launches next-generation ALLEVYN™ COMPLETE CARE Foam Dressing - designed for high performance in wound management and pressure injury prevention
10/03/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, recently announced the launch of ALLEVYN ♢ COMPLETE CARE Foam Dressing, featuring proprietary technologies and performance backed by a portfolio of [...]
Roche Annual General Meeting 2026
10/03/2026
Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election were confirmed 39th consecutive dividend [...]
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA
10/03/2026
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy BLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement [...]
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
10/03/2026
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed [...]
Experts at Park Mental Health Announce New Therapeutic Approach: Highlighting the Role of Community Support in Recovery
10/03/2026
Park Mental Health highlights the importance of supportive relationships in mental health journey SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- It can be a difficult task to support an individual struggling with mental [...]
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026
10/03/2026
SANTA ANA, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
10/03/2026
ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatment Children ages 2-5 who achieved disease clearance and who switched to proactive twice- [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 32,13 SEK per day at pharmacies throughout Sweden AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 3.39 EUR per day at pharmacies throughout Finland AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
10/03/2026
Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 [...]
Coloplast A/S - Allocation of Share Options
10/03/2026
Report on transactions of executives and related parties in Coloplast shares and related securities According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives [...]
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026
— The new pricing structure is made available as of February for 566,13 ISK per day at pharmacies throughout Iceland AMSTERDAM, March 10, 2026 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, a biopharmaceutical [...]
Nominations Now Open for PerfectServe’s Sixth Annual Nurses of Note Awards Program
10/03/2026
2026 program to highlight nurse leadership and excellence in clinical innovation, patient-centered care, culture & retention, and care team communication MIAMI, March 10, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a [...]
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
10/03/2026
-- Enrollment begins in the FDA-authorized FINALE pivotal trial evaluating FemBloc, a first-of-its-kind non-surgical permanent birth control, following positive clinical data -- ATLANTA, March 10, 2026 (GLOBE NEWSWIRE [...]
Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay
10/03/2026
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics [...]
Longeveron Announces Private Placement of up to $30 Million
10/03/2026
$15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules [...]

Pages